check_circleStudy Completed

Arterial hypertension

Bayer Identifier:

14675

ClinicalTrials.gov Identifier:

NCT01071681

EudraCT Number:

Not Available

EU CT Number:

Not Available
Survey to assess why people are not responding to treatment in Hypertension

Trial purpose

This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients

Key Participants Requirements

Sex

Both

Age

18 - N/A
  • - Men or women over 18
    - Hypertensive patients
    - Uncontrolled hypertension (blood pressure >/=140/90 mmHg on the day of consultation or >/=130/80 mmHg in diabetic patients or in patients suffering from kidney failure, or in elderly patients with a systolic blood pressure >/=150 mmHg (in the absence of orthostatic hypotension)
    - Patients treated with a combination, fixed or not, of Renin-Angiotensin System Blocker (RASB) + Hydrochlorothiazide (HCTZ)
    - Patients examined in common medical care practice, whatever the reason for consultation
    - Patients informed of the study

Trial summary

Enrollment Goal
1589
Trial Dates
November 2009 - February 2012
Phase
N/A
Could I Receive a placebo
No
Products
Kinzal/Pritor (Telmisartan, BAY68-9291)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, France

Primary Outcome

  • Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit:- do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic
    date_rangeTime Frame:
    on day 1
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Analyses of the factors that had an impact on the therapeutic decision
    date_rangeTime Frame:
    on day 1
    enhanced_encryption
    Safety Issue:
    No

Trial design

Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.